留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

中国肾移植排斥反应临床诊疗指南(2016版)

中华医学会器官移植学分会 中国医师协会器官移植医师分会

中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肾移植排斥反应临床诊疗指南(2016版)[J]. 器官移植, 2016, 7(5): 332-338. doi: 10.3969/j.issn.1674-7445.2016.05.002
引用本文: 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肾移植排斥反应临床诊疗指南(2016版)[J]. 器官移植, 2016, 7(5): 332-338. doi: 10.3969/j.issn.1674-7445.2016.05.002
Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physician of Chinese Medical Doctor Association. Guideline on clinical diagnosis and treatment for rejection of renal transplantation in China(2016 edition)[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 332-338. doi: 10.3969/j.issn.1674-7445.2016.05.002
Citation: Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physician of Chinese Medical Doctor Association. Guideline on clinical diagnosis and treatment for rejection of renal transplantation in China(2016 edition)[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 332-338. doi: 10.3969/j.issn.1674-7445.2016.05.002

中国肾移植排斥反应临床诊疗指南(2016版)

doi: 10.3969/j.issn.1674-7445.2016.05.002
基金项目: 

国家自然科学基金 81370578

国家自然科学基金 81570680

详细信息
  • 中图分类号: R617, R365

Guideline on clinical diagnosis and treatment for rejection of renal transplantation in China(2016 edition)

  • 摘要: 排斥反应是影响移植肾长期存活的首要独立危险因素,是亟待解决的瓶颈问题。中华医学会器官移植学分会和中国医师协会器官移植医师分会组织国内专家,总结各中心肾移植的临床经验,依据Banff 2013标准,编写了本部指南,希望能为相关临床科室提供工作指引。

     

  • [1] Broecker V, Mengel M. The significance of histological diagnosis in renal allograft biopsies in 2014[J]. Transpl Int, 2015, 28(2):136-143. doi: 10.1111/tri.2015.28.issue-2
    [2] 孙世澜.肾衰竭诊断治疗学[M].人民军医出版社, 2012.
    [3] Yaich S. ABO-incompatible kidney transplantation[J]. Saudi J Kidney Dis Transpl, 2013, 24(3):463-472. doi: 10.4103/1319-2442.111009
    [4] Muramatsu M, Gonzalez HD, Cacciola R, et al. ABO incompatible renal transplants: good or bad?[J]. World J Transplant, 2014, 4(1):18-29. doi: 10.5500/wjt.v4.i1.18
    [5] Matsuo N, Yamamoto H, Kobayashi A, et al. A case of accelerated acute rejection after ABO-compatible living unrelated kidney transplantation[J]. Clin Transplant, 2009, 23(Suppl 20):23-26. doi: 10.1111/j.1399-0012.2009.01004.x/references
    [6] Jalalzadeh M, Mousavinasab N, Peyrovi S, et al. The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome[J]. Nephrourol Mon, 2015, 7(1):e24439. http://numonthly.com/24439.abstract
    [7] Randhawa P. T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenges and clinical significance[J]. Curr Opin Organ Transplant, 2015, 20(3):325-332. doi: 10.1097/MOT.0000000000000189
    [8] Zhang RB. Clinical management of kidney allograft dysfunction[J]. Open J Organ Transpl Surg, 2014, 4(2): 7-14. doi: 10.4236/ojots.2014.42002
    [9] Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase Ⅲ clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation[J]. Transplantation, 1998, 66(1):29-37. doi: 10.1097/00007890-199807150-00005
    [10] Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3):S1-S155. http://www.kdigo.org/clinical_practice_guidelines/pdf/KITxpGL_SupplementaryTables.pdf
    [11] Salvadori M, Bertoni E. Acute antibody-mediated rejection in kidney transplantation: clinical and therapeutic aspects[J]. J Nephrol Ther, 2013, 4(1): 146. http://planthealth.org/article/acute-antibody-mediated-rejection-kidney-transplantation-clinical-and-therapeutic-aspects
    [12] Melk A, Schmidt BM, Braun H, et al. Effects of donor age and cell senescence on kidney allograft survival[J]. Am J Transplant, 2009, 9(1):114-123. https://www.researchgate.net/profile/Philip_Halloran/publication/23768668_Effects_of_Donor_Age_and_Cell_Senescence_on_Kidney_Allograft_Survival/links/5408f2140cf2822fb738bb8f.pdf?inViewer=true&disableCoverPage=true&origin=publication_detail
    [13] Allen U, Humar A, Limaye A, et al. Discipline of transplant infectious diseases (ID). foreword[J]. Am J Transplant, 2009, 9(Suppl 4):S1-S2. https://www.researchgate.net/publication/51441218_Discipline_of_Transplant_Infectious_Diseases_ID_Foreword
    [14] Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial[J]. Am J Transplant, 2004, 4(3):438-443. doi: 10.1111/ajt.2004.4.issue-3
    [15] Haririan A. Current status of the evaluation and management of antibody-mediated rejection in kidney transplantation[J]. Curr Opin Nephrol Hypertens, 2015, 24(6):576-581. doi: 10.1097/MNH.0000000000000167
    [16] Morath C, Zeier M. Transplantation: molecular diagnosis of kidney transplant rejection[J]. Nat Rev Nephrol, 2014, 10(8):429-430. doi: 10.1038/nrneph.2014.106
    [17] Wilflingseder J, Reindl-Schwaighofer R, Sunzenauer J, et al. MicroRNAs in kidney transplantation[J]. Nephrol Dial Transplant, 2015, 30(6):910-917. doi: 10.1093/ndt/gfu280
    [18] Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches[J]. Am J Transplant, 2014, 14(2):255-271. doi: 10.1111/ajt.12589
    [19] Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes[J]. Transplant Rev, 2009, 23(1):34-46. doi: 10.1016/j.trre.2008.08.004
    [20] Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review[J]. J Transplant, 2012:193724. https://www.hindawi.com/journals/jtrans/2012/193724/
    [21] Kim M, Martin ST, Townsend KR, et al. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options[J]. Pharmacotherapy, 2014, 34(7):733-744. doi: 10.1002/phar.2014.34.issue-7
    [22] Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24):2326-2333. doi: 10.1056/NEJMoa020009
    [23] Heemann U, Lutz J. Pathophysiology and treatment options of chronic renal allograft damage[J]. Nephrol Dial Transplant, 2013, 28(10):2438-2446. doi: 10.1093/ndt/gft087
    [24] Bhatti AB, Usman M. Chronic renal transplant rejection and possible anti-proliferative drug targets[J]. Cureus, 2015, 7(11):e376. http://assets.cureus.com/uploads/review_article/pdf/3505/1446833842-20151106-1538-182mb4z.pdf
    [25] Tanabe K, Inui M. Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation[J]. Clin Transplant, 2013, 27(Suppl 26):2-8. doi: 10.1111/ctr.12260/references
    [26] Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation[J]. Transplantation, 2013, 95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc
  • 加载中
计量
  • 文章访问数:  140
  • HTML全文浏览量:  99
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-05-27
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2016-09-15

目录

    /

    返回文章
    返回